Summary

Copper peptides are small peptide sequences that bind copper ions (Cu²⁺) with high affinity, forming complexes that influence tissue repair, collagen synthesis, and inflammation. The most studied are GHK-Cu (glycyl-L-histidyl-L-lysine-copper) and AHK-Cu (alanine-histidine-lysine-copper). Research spans wound healing, skin ageing, hair growth, and regenerative medicine. This overview entry complements the individual GHK-Cu and AHK-Cu profiles.

Mechanism

Copper peptides chelate Cu²⁺ ions and facilitate their delivery to intracellular copper-dependent enzymes (lysyl oxidase, tyrosinase, SOD). GHK-Cu modulates expression of over 4,000 human genes — upregulating tissue remodelling genes (collagen I/III, elastin, MMPs) and downregulating pro-inflammatory and fibrotic pathways. AHK-Cu stimulates dermal papilla cell proliferation and may upregulate VEGF, relevant to hair follicle research.

Evidence base

Evidence grade: Moderate

Wound healing data in animal models is robust, with limited human clinical evidence (one underpowered Phase II trial in diabetic ulcers). Skin ageing data relies largely on industry-sponsored cosmetic studies with limited independent replication. AHK-Cu hair growth data is primarily in vitro and animal. No large-scale randomised controlled trials exist for systemic copper peptide use. Evidence is strongest for topical GHK-Cu in dermatological applications.

Protocols

Topical research: 0.05–3% GHK-Cu in cream/serum, applied 1–2× daily. Subcutaneous research: 1–2 mg per dose discussed in research communities, though published clinical data for this route is extremely limited. In vitro concentrations: 10⁻¹² to 10⁻⁴ M depending on model. No standardised clinical dosing protocol exists for systemic administration. All information for research and educational purposes only.

Copper peptides are legal for research purposes in the UK. Not controlled substances under the Misuse of Drugs Act 1971. Not licensed medicines for any indication when sold as research chemicals. GHK-Cu is permitted as a cosmetic ingredient under the UK Cosmetics Regulation. Research-peptide products must be labelled "not for human consumption" per MHRA guidance.

Vendor notes

Seek vendors providing third-party COAs confirming peptide purity (≥98%) and copper content. Verify that the copper-peptide ratio is correctly specified (1:1 for GHK-Cu). Avoid vendors making medical claims. See the vendor vetting guide for evaluation criteria.

References

  1. Pickart L, et al. A naturally occurring copper chelating peptide from human plasma. Nature. 1973;246(5430):176–178. doi:10.1038/246176a0
  2. Pickart L. The human skin tripeptide, GHK, and copper: a potential anti-aging target. J Aging Res Clin Pract. 2012;1(2):131–136.
  3. Mulder GD, et al. A study of the effects of a copper peptide gel on diabetic foot ulcers. Wound Repair Regen. 1994;2(4):253–259.
  4. Finkley JB, et al. A double-blind, placebo-controlled study of copper peptide cream in the treatment of photodamaged skin. J Cosmet Dermatol. 2015;14(2):121–127.
  5. Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834–839. doi:10.1007/BF02978837
  6. Gruchlik A, et al. Effects of glycyl-L-histidyl-L-lysyl-copper(II) on the secretion of IL-6 and TNF-α in human keratinocytes. Pharmacol Rep. 2013;65(1):207–213.
  7. Kang YA, et al. Ergothioneine and GHK-Cu inhibit UVB-induced oxidative stress and MMP expression. Int J Cosmet Sci. 2018;40(5):498–505.
  8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236–247. doi:10.3390/cosmetics2030236